Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Linzhi, Zhang"'
Autor:
Rui Wen, Miaoran Wang, Wei Bian, Haoyue Zhu, Ying Xiao, Jing Zeng, Qian He, Yu Wang, Xiaoqing Liu, Yangdi Shi, Linzhi Zhang, Zhe Hong, Bing Xu
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
BackgroundThis investigation seeks to ascertain the efficacy of various machine learning models in forecasting early neurological deterioration (END) following thrombolysis in patients with acute ischemic stroke (AIS).MethodsEmploying data from the S
Externí odkaz:
https://doaj.org/article/9474e891e6f84e3dacd5ea1bdeee0ecf
Autor:
Qian He, Miaoran Wang, Haoyue Zhu, Ying Xiao, Rui Wen, Xiaoqing Liu, Yangdi Shi, Linzhi Zhang, Yu Wang, Bing Xu
Publikováno v:
Frontiers in Aging Neuroscience, Vol 16 (2024)
BackgroundWe aimed to use lactate dehydrogenase (LDH) as a marker of inflammation burden and quantify post-stroke inflammation’s direct and indirect effect on functional disability.MethodsWe analyzed 5,129 patients with acute ischemic stroke (AIS)
Externí odkaz:
https://doaj.org/article/837fda7bacc0473fbddd532b2130b67c
Autor:
Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi, Yinying Lu
Publikováno v:
Cancer Biology & Medicine, Vol 19, Iss 6, Pp 802-817 (2022)
Hepatocellular carcinoma (HCC), one of the most common malignant tumors in China, severely threatens the life and health of patients. In recent years, precision medicine, clinical diagnoses, treatments, and innovative research have led to important b
Externí odkaz:
https://doaj.org/article/ed21bff4344b455f8f63e70de26f4518
Autor:
Timothy F. Baars, Richard Huis in ‘t Veld, Linzhi Zhang, Maaike Koopmans, Duncan McLean, Allard W. Martinius, Hemmo A. Abels
Publikováno v:
Netherlands Journal of Geosciences, Vol 102 (2023)
Orbital driven climate control on sedimentation produces regional, stratigraphically repetitive characters and so cyclostratigraphic correlation can improve correlation and identify stratigraphic trends in borehole sections. This concept is commonly
Externí odkaz:
https://doaj.org/article/b24d34e41eaf418ba0d7165085a67475
Autor:
Jin Lei, Bowen Chen, Meiru Song, Linzhi Zhang, Xinfeng Zhang, Xiaoqiang Gao, Yinyin Li, Yinying Lu, Shi Zuo
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Tyrosine kinase inhibitors (TKI) in combination with programmed cell death-1 (PD-1) inhibitors become the potential treatment modality for patients undergoing unresectable hepatocellular carcinoma (uHCC) in the first-line setting. However
Externí odkaz:
https://doaj.org/article/135e2d16fed6459cb6e8942aec72b702
Autor:
Tao Yan, Chenyang Huang, Jin Lei, Qian Guo, Guodong Su, Tong Wu, Xueyuan Jin, Caiyun Peng, Jiamin Cheng, Linzhi Zhang, Zherui Liu, Terence Kin, Fan Ying, Suthat Liangpunsakul, Yinyin Li, Yinying Lu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundWith the increasing incidence and prevalence of alcoholic liver disease, alcohol-related hepatocellular carcinoma has become a serious public health problem worthy of attention in China. However, there is currently no prognostic prediction
Externí odkaz:
https://doaj.org/article/1c28651473bd4e3583ae689e634734bc
Autor:
Jin, Lei, Tao, Yan, Linzhi, Zhang, Bowen, Chen, Jiamin, Cheng, Xiaoqiang, Gao, Zherui, Liu, Yinyin, Li, Shi, Zuo, Yinying, Lu
Publikováno v:
Hepatology International. 17:281-290
Programmed cell death protein-1 (PD-1) inhibitors plus tyrosine kinase inhibitor (TKI) have dramatically improved survival of patients with advanced hepatocellular carcinoma (HCC). However, the risk of hepatitis B virus (HBV) reactivation from these
Autor:
Jin Lei, Sibo Yang, Bowen Chen, Linzhi Zhang, Tao Yan, Gangqi Yang, Yue Chen, Yinyin Li, Yinying Lu, Shi Zuo
Publikováno v:
Journal of Hepatocellular Carcinoma.
Jin Lei,1,* Sibo Yang,1,* Bowen Chen,2,* Linzhi Zhang,3 Tao Yan,3 Gangqi Yang,1 Yue Chen,1 Yinyin Li,3 Yinying Lu,1,3,4 Shi Zuo1,5 1School of Clinical Medicine, Guizhou Medical University, Guiyang, Peopleâs Republic of China; 2 302 C
Autor:
Bowen Chen, Linzhi Zhang, Jiamin Cheng, Tong Wu, Jin Lei, Xu Yang, Rongling Zhang, Rifaat Safadi, Yinyin Li, Tongguo Si, Yinying Lu
Publikováno v:
Drug Design, Development and Therapy.
Bowen Chen,1,2,* Linzhi Zhang,2,3,* Jiamin Cheng,2,* Tong Wu,2 Jin Lei,2,4 Xu Yang,5 Rongling Zhang,6 Rifaat Safadi,7 Yinyin Li,2 Tongguo Si,3 Yinying Lu1,2,8,9 1Peking University 302 Clinical Medical School, Beijing, Peopleâs Republ
Autor:
Xu Yang, Bowen Chen, Yanyu Wang, Yunchao Wang, Junyu Long, Nan Zhang, Jingnan Xue, Ziyu Xun, Linzhi Zhang, Jiamin Cheng, Jin Lei, Huishan Sun, Yiran Li, Jianzhen Lin, Fucun Xie, Dongxu Wang, Jie Pan, Ke Hu, Mei Guan, Li Huo, Jie Shi, Lingxiang Yu, Lin Zhou, Jinxue Zhou, Zhenhui Lu, Xiaobo Yang, Yilei Mao, Xinting Sang, Yinying Lu, Haitao Zhao
Introduction Combining lenvatinib with a programmed cell death protein-1 (PD-1) inhibitor has been explored for the treatment of un-resectable hepatocellular carcinoma (uHCC). This study aimed to investigate the real-world efficacy of and prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b2312d755476c72e6d180252ec2cab6
https://doi.org/10.21203/rs.3.rs-2152996/v1
https://doi.org/10.21203/rs.3.rs-2152996/v1